Granite Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Granite Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-24,604	Closed	-$2.66M	–	321
2019 Q4	$2.66M	Sell	24,604 -28,288	-53%	-$3.03M	0.13%	167
2019 Q3	$5.18M	Sell	52,892 -15,235	-22%	-$1.72M	0.27%	106
2019 Q2	$8.92M	Buy	68,127 +3,621	+6%	+$467K	0.48%	81
2019 Q1	$8.72M	Buy	64,506 +5,466	+9%	+$680K	0.49%	81
2018 Q4	$5.75M	Buy	59,040 +14,671	+33%	+$1.73M	0.42%	93
2018 Q3	$6.17M	Sell	44,369 -2,917	-6%	-$366K	0.36%	97
2018 Q2	$5.87M	Sell	47,286 -1,285	-3%	-$150K	0.37%	100
2018 Q1	$5.41M	Buy	48,571 +11,870	+32%	+$1.42M	0.36%	100
2017 Q4	$4.39M	Buy	+36,701	New	+$4.47M	0.28%	108

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Granite Investment Partners's ALXN Position: Q1 2020 in Review

Granite Investment Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 24,604 shares — an estimated $2.66M sold.

Granite Investment Partners first reported a position in ALXN in Q4 2017 and held it in 9 quarters. The position peaked at $8.92M in Q2 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Granite Investment Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Granite Investment Partners sold 24,604 Alexion Pharmaceuticals shares in Q1 2020, an estimated $2.66M.
Granite Investment Partners first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Granite Investment Partners's Alexion Pharmaceuticals position peaked at $8.92M in Q2 2019.
653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Granite Investment Partners's 13F filing for Q1 2020, filed 14 May 2020.